- Home
- KRMD vs LRMR Comparison
KRMD vs LRMR Comparison
Compare KRMD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | LRMR |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 316.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KRMD | LRMR |
|---|---|---|
| Price | $5.62 | $3.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $6.00 | ★ $16.71 |
| AVG Volume (30 Days) | 182.5K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | N/A |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.12 | N/A |
| 52 Week Low | $1.86 | $1.61 |
| 52 Week High | $6.61 | $5.37 |
Technical Indicators
Market Signals| Indicator | KRMD | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 41.31 |
| Support Level | $5.31 | $3.31 |
| Resistance Level | $6.61 | $4.01 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 27.73 | 14.34 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.